TY - JOUR
T1 - Comparative analysis of IFN-γ B7.1 and antisense TGF-β gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma
AU - Wu, Rita S.
AU - Kobie, James J.
AU - Besselsen, David G.
AU - Fong, Tim C.
AU - Mack, Vivian D.
AU - McEarchern, Julie A.
AU - Akporiaye, Emmanuel T.
N1 - Funding Information:
Acknowledgements The authors wish to thank Barb Carolus and Dr. Samuel Schluter for their expert technical assistance. We very much appreciate the help of Dr. Tina Trevor and Sara O. Bellomo for their critical review of this manuscript. We also thank Dona T. Wu for performing the statistical analysis. This work was sup- ported by NIH Grant CA6929–01A, the Arizona Disease Control Research Commission (contract #9801 and #20003) (E.T.A.) and a Sigma Xi Research Award for Grants-in-Aid (R.S.W.).
PY - 2001
Y1 - 2001
N2 - Cancer progression is attributed in part to immune evasion strategies that include lack of co-stimulation, down-regulation of cell surface MHC molecules, and secretion of immunosuppressive factors, such as transforming growth factor-β (TGF-β). Gene therapy has been employed to counter these mechanisms of immune evasion by transference of B7.1, IFN-γ or antisense TGF-β genes into tumor cells, resulting in cell surface expression of B7.1, upregulation of MHC class I and class II molecules, or elimination of tumor-derived TGF-β, respectively. Although each of these transgenes has been shown to alter tumorigenicity in murine models, a direct comparison of their efficacy has not been performed. In this study, we have employed a very aggressive, poorly immunogenic and highly metastatic mammary model, 4T1, to compare the efficacy of B7.1, IFN-γ and antisense TGF-β gene transfer in stimulating an anti-tumor response. We demonstrate that both IFN-γ and antisense TGF-β gene expression significantly reduced the tumorigenicity of these cells compared to mock transduced cells, with IFN-γ having a greater effect. In contrast, B7.1 gene transfer did not affect the tumorigenicity of 4T1 cells. The anti-tumor response directed against antisense TGF-β-expressing 4T1 tumors was mediated by CD4+ and CD8+ T cells. However, CD8+ T cells, and not CD4+ T cells, appeared to mediate the anti-tumor response against IFN-γ-expressing tumors. Treatment of tumor-bearing animals with IFN-γ or antisense TGF-β gene-modified tumor cell vaccines reduced the number of clonogenic metastases to the lungs and liver compared to treatment with mock-transduced cells. Finally, in a residual disease model in which the primary tumor was excised and mice were vaccinated with irradiated tumor cells, treatment of mice with vaccinations consisting of 4T1 cells expressing both antisense TGF-β and IFN-γ genes was the most effective in prolonging survival.
AB - Cancer progression is attributed in part to immune evasion strategies that include lack of co-stimulation, down-regulation of cell surface MHC molecules, and secretion of immunosuppressive factors, such as transforming growth factor-β (TGF-β). Gene therapy has been employed to counter these mechanisms of immune evasion by transference of B7.1, IFN-γ or antisense TGF-β genes into tumor cells, resulting in cell surface expression of B7.1, upregulation of MHC class I and class II molecules, or elimination of tumor-derived TGF-β, respectively. Although each of these transgenes has been shown to alter tumorigenicity in murine models, a direct comparison of their efficacy has not been performed. In this study, we have employed a very aggressive, poorly immunogenic and highly metastatic mammary model, 4T1, to compare the efficacy of B7.1, IFN-γ and antisense TGF-β gene transfer in stimulating an anti-tumor response. We demonstrate that both IFN-γ and antisense TGF-β gene expression significantly reduced the tumorigenicity of these cells compared to mock transduced cells, with IFN-γ having a greater effect. In contrast, B7.1 gene transfer did not affect the tumorigenicity of 4T1 cells. The anti-tumor response directed against antisense TGF-β-expressing 4T1 tumors was mediated by CD4+ and CD8+ T cells. However, CD8+ T cells, and not CD4+ T cells, appeared to mediate the anti-tumor response against IFN-γ-expressing tumors. Treatment of tumor-bearing animals with IFN-γ or antisense TGF-β gene-modified tumor cell vaccines reduced the number of clonogenic metastases to the lungs and liver compared to treatment with mock-transduced cells. Finally, in a residual disease model in which the primary tumor was excised and mice were vaccinated with irradiated tumor cells, treatment of mice with vaccinations consisting of 4T1 cells expressing both antisense TGF-β and IFN-γ genes was the most effective in prolonging survival.
KW - Antisense
KW - B7.1
KW - Gene therapy
KW - Mammary cancer
KW - TGF-βIFN-γ
UR - http://www.scopus.com/inward/record.url?scp=0034926056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034926056&partnerID=8YFLogxK
U2 - 10.1007/s002620100197
DO - 10.1007/s002620100197
M3 - Article
C2 - 11499806
AN - SCOPUS:0034926056
SN - 0340-7004
VL - 50
SP - 229
EP - 240
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 5
ER -